Atossa Therapeutics
ATOS
16 hedge funds and large institutions have $536K invested in Atossa Therapeutics in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
3% more capital inflows, than outflows
Capital inflows: $136K | Capital outflows: $132K
1.14% less ownership
Funds ownership: 5.18% → 4.04% (-1.1%)
6% less funds holding
Funds holding: 17 → 16 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.5K |
| 3 |
Virtu KCG Holdings
New York
|
+$15.7K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$13.9K |
| 5 |
Two Sigma Securities
New York
|
+$9.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Anson Funds Management
Dallas,
Texas
|
-$102K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12K |
| 3 |
Goldman Sachs
New York
|
-$11K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5K |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
-$1.85K |
ATOS Hedge Fund Activity: Q1 2016 in Review
16 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2016, worth a combined $536K — up 7% from $501K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATOS and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $55.6K. The largest seller was Anson Funds Management, exiting entirely with an estimated $102K sold.
- 16 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2016, down from 17 in Q4 2015.
- Funds reported $536K of Atossa Therapeutics stock for Q1 2016, up 7% quarter-over-quarter.
- 3 funds opened new Atossa Therapeutics positions in Q1 2016 and 4 closed out, a net change of -1 holder.
- The largest Atossa Therapeutics buyer in Q1 2016 was Renaissance Technologies, an estimated $55.6K added.
- The largest Atossa Therapeutics seller in Q1 2016 was Anson Funds Management, an estimated $102K sold.
Based on aggregated 13F filings for Q1 2016.